AstraZeneca PLC made progress on two fronts in its quest to build its oncology portfolio with the early unblinding of the Phase III ADAURA clinical trial of Tagrisso (osimertinib) in the adjuvant lung cancer setting and with US Food and Drug Administration approval for Koselugo (selumetinib) in its first-ever indication.
Dave Fredrickson, executive vice president of the company’s oncology business unit, told Scrip that the news announced on 10 and...






